95
Participants
Start Date
February 6, 2014
Primary Completion Date
August 17, 2016
Study Completion Date
August 17, 2016
DNIB0600A
DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.
PLD
PLD will be administered at a dose of 40 mg/m\^2 IV every 4 weeks.
UZ Leuven Gasthuisberg, Leuven
CHU Sart-Tilman, Liège
Magee Womens Hospital, Pittsburgh
Johns Hopkins Uni; Oncology Center, Baltimore
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Universitario 12 de Octubre, Madrid
HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid
Florida Cancer Specialists., St. Petersburg
Sarah Cannon Cancer Center, Germantown
Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes, Lyon
Hematology & Oncology Associates, Covington
Oklahoma University Health Sciences Center, Oklahoma City
Hôpital Européen Georges Pompidou, Paris
HOPITAL TENON; Cancerologie Medicale, Paris
St. Joseph'S Hospital & Medical Center, Phoenix
HonorHealth Research Institute - Pima Center, Scottsdale
University of California Irvine Medical Center, Orange
Institut Gustave Roussy, Villejuif
Northwest Cancer Specialists, P.C., Tualatin
Massachusetts General Hospital, Boston
Dana Farber Cancer Inst., Boston
Beth Israel Deaconess Medical Center, Boston
Women & Infants Hospital, Providence
London Regional Cancer Centre, London
Princess Margaret Hospital, Toronto
Chum Hopital Notre Dame; Centre D'Oncologie, Montreal
Bialostockie Centrum Onkologi, Bialystok
Wojewodzkie Centrum Onkologii, Gdansk
Wojskowy Instytut Medyczny Centralny Szpital Kliniczny MON, Warsaw
Hospital Universitario Vall d'Hebron; Servicio de Neumologia, Barcelona
Hospital Clinic de Barcelona, Barcelona
Sarah Cannon Research Institute, London
Christie Hospital, Manchester
The Clatterbridge Cancer Centre NHS Foundation Trust, Metropolitan Borough of Wirral
The Royal Marsden Hospital, Sutton
Royal Marsden NHS Foundation Trust, Sutton, Surrey
Lead Sponsor
Genentech, Inc.
INDUSTRY